SIOG (International Society of Geriatric Oncology) recommendations for anthracycline use in the elderly

  • Matti Aapro | maapro@genolier.net Multidisciplinary Oncology Institute, Genolier, Switzerland.

Abstract

A taskforce of the International Society of Geriatric Oncology (SIOG) has recently submitted recommendations on the use of anthracyclines in elderly patients. Despite the aging of the population and the high proportion of elderly individuals in the population of patients with non-Hodgkin’s lymphoma, the development of specialist expertise in the treatment of elderly patients with cancer is relatively recent. Treatment of the elderly is complex because they are a highly heterogeneous population, with large variations in health status, comorbidities and life expectancy. In addition, these patients are generally more susceptible than young patients to the cardiotoxic effects of anthracyclines. Strategies for assessing elderly patients with cancer, reducing the risk of congestive heart failure, and assessing the cardiotoxic effects of treatments are discussed. In addition, a summary of the SIOG recommendations is presented.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2011-10-28
Keywords:
SIOG recommendations, non-Hodgkin’s lymphoma, elderly patients, anthracycline, treatment, cardiotoxicity
Statistics
  • Abstract views: 1101

  • PDF: 444
  • HTML: 398
How to Cite
Aapro, M. (2011). SIOG (International Society of Geriatric Oncology) recommendations for anthracycline use in the elderly. Hematology Reports, 3(s3), e6. https://doi.org/10.4081/hr.2011.s3.e6